期刊文献+

气相色谱法测定富马酸卢帕他定中三乙胺的含量 被引量:2

Determination of Residual Triethylamine in Rupatadine Fumarate by Gas Chromatography
下载PDF
导出
摘要 建立了富马酸卢帕他定原料药中三乙胺残留量的测定方法。采用顶空气相色谱法。色谱柱为CP-Sil8 CB(30 m×0.32 mm×1.00μm);氢火焰离子化检测器(FID),载气为氮气,流速为1.5 mL·min^(-1);检测器温度为250℃;进样口温度为150℃;柱温采用程序升温,初始温度40℃,维持5 min,再以20℃·m in^(-1)的速率升温至220℃,维持4 min;顶空瓶平衡温度80℃,平衡时间30 min。FID检测器测定三乙胺的残留量。结果表明,三乙胺在0.91~45.47μg·mL^(-1)(r2=0.9996)范围时线性关系良好,平均回收率为100.9%,RSD为1.7%(n=9),建立的方法准确、可靠、灵敏高,适用于测定富马酸卢帕他定原料药中三乙胺残留检测。 To establish a method for determination of residual triethylamine in Rupatadine Fumarate by GC. It was quantitatively determined by headspace gas chromatography (GC) with CP-Si18 CB column (30 m×0.32 mm×1.00μm)and FID detector. The carrier gas was nitrogen and the flow rate was 1.5 mL·min-1. The temperature of the injection port was maintaining at 150℃ and the temperature of detector was 250℃. The oven introduced sequential increasing of temperature programing. The initial column temperature was 40℃, maintained 5 min, then raised the temperature to 220℃ at a rate of 20℃·min-1, and maintained 4 min,. The headspace oven was set at a temperature of 80℃ for 30 min. Results showed that there was a good linearity within the range of 0.91-45.47μg.ml-1 for triethylamine. The correlation coefficient was 0.9996. The average recovery rate was 100.9 %. The RSD of precision was 1.7 %(n=9), This method is accurate, reliable and sensitive for the determination of the residual quantity of triethylamine in Rupatadine Fumarate, and this method provides an idea for the determination of residual triethylamine in fumaric acid, citric acid, hydrochloric acid and other drugs.
作者 马振千 鹿贵花 印嘉佳 汤海燕 Ma Zhengqian, Lu Guihua, Yin Jiajia, Tang Haiyan(Research Department ,Yangtze River Pharmaceutical Group Jiangsu HAI-CI Biological Pharmaceutical Co.,Ltd, Taizhou 225321, Chin)
出处 《广东化工》 CAS 2018年第14期213-214,212,共3页 Guangdong Chemical Industry
关键词 富马酸卢帕他定 顶空气相色谱法 三乙胺 rupatadine Fumarate gas chromatography trietbylamine
  • 相关文献

参考文献9

二级参考文献50

  • 1辛水波,吴范宏.卢帕他定的合成[J].中国新药杂志,2005,14(4):451-452. 被引量:2
  • 2卜今,陈志强.卢帕他定——新型的组胺H1受体和血小板活化因子受体双重拮抗剂[J].中国中西医结合皮肤性病学杂志,2006,5(3):182-184. 被引量:7
  • 3崔岚,安富荣.治疗慢性乙型肝炎的新型药物[J].中国药师,2007,10(7):692-694. 被引量:6
  • 4周海钧.药品注册的国际技术要求(质量部分)[M].北京:人民卫生出版社,2000:87.
  • 5国家药典委员会.中华人民共和国药典(二部)[S].2005年版.北京:化学工业出版社,2005:附录83-90.
  • 6国家药典委员会编.中国药典[s].二部.北京:化学工业出版社.2010.附录14.472.
  • 7Ch.P(2010)Vol.Ⅱ(中国药典2010年版.二部[S].2010:973-974.
  • 8Christie Pc, Henderson Wr Jr. Lipid inflammatory meditors : leukotriences, prostaglandins, platelet-activating factor[ J].Clin Allergy Immuno1,2002,16 : 233-254.
  • 9Manuel M, Marta G, Dolors B, et al. Rupatadinc, a new po- tent, orally activating factor (PAF) [ J ]. Pharmacol Exp T- her,201M ,280( 1 ) :114-121.
  • 10Bartea J, Valero A1, Cuvillo Da, et al. Interactions of the H.antihistamines [ J ]. Investig Allergol Clin Immunol, 2006,16 (Suppl 1 ) :29-36.

共引文献47

同被引文献22

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部